Purpose: Information on the status of human epidermal growth factor receptor 2 (HER2) is important for treatment planning in breast cancer; therefore, equivocal results of HER2 overexpression obtained using immunohistochemical staining (IHC) require additional evaluation regarding HER2 amplification, which can be obtained by other techniques such as fluorescence in situ hybridization (FISH) assay. The silver-enhanced in situ hybridization (SISH) technique is known to be comparable with FISH and can be performed under a bright field microscope. In this study, the authors evaluated the concordance between the results obtained by IHC and SISH used for determining HER2 status. Methods: Paraffin-embedded tissues from 511 breast cancer patients were prepared and the medical records of the patients were reviewed. HER2 amplification status was evaluated by SISH assay by determining the HER2/chromosome 17 ratio or HER2 copy number status. The slides were blindly reviewed without IHC information. Results: Among the collected tissues, invasive ductal carcinoma was detected in 440 patients (86.1%) and 27 (5.3%) showed ductal carcinoma in situ. The concordance rate between the results obtained by IHC and SISH was 90.6% (κ= 0.723). Two cases of negative IHC results had equivocal SISH results. Conclusion: SISH was found to be a useful method for evaluating HER2 status in case of an equivocal result of IHC. 
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